Novartis购买Anthos治疗药物,价值高达31亿美元,用于推进中风预防药物。 Novartis buys Anthos Therapeutics for up to $3.1 billion to advance a stroke-preventing drug.

诺华制药公司,一家大制药公司, 正在购买Anthos治疗药物, 一家小型生物制药公司, 价值高达31亿美元。 Novartis, a major pharmaceutical company, is acquiring Anthos Therapeutics, a smaller biopharmaceutical firm, for up to $3.1 billion. 这项协议旨在推动培养ABelacimab,这是一种用于预防白发性纤维化和癌症患者中中风和血液凝血的药物。 This deal aims to advance the development of abelacimab, a drug for preventing strokes and blood clots in atrial fibrillation and cancer patients. Novartis将提前支付9.25亿美元,根据里程碑,再支付高达21.5亿美元。 Novartis will pay $925 million upfront, with up to $2.15 billion more based on milestones. 预计该收购将于2025年上半年关闭。 The acquisition is expected to close in the first half of 2025.